Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | F13A1 | P00488 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109087 | 1.00 | CYP1A2 (0.57) | CYP1A2MEN1KMT2ASMN1; SMN2PAOX | |
| SCHEMBL5670730 | 1.00 | CYP1A2 (0.57) | CYP1A2MEN1KMT2ASMN1; SMN2PAOX | |
| SCHEMBL6698302 | 1.00 | CYP1A2 (0.57) | CYP1A2MEN1KMT2ASMN1; SMN2PAOX | |
| SCHEMBL6698407 | 1.00 | CYP1A2 (0.57) | CYP1A2MEN1KMT2ASMN1; SMN2PAOX | |
| Hydrochloric Acid SCHEMBL20543020 | 0.98 | SMN1; SMN2 (0.55) | CYP1A2MEN1KMT2ASMN1; SMN2PAOX | |
| Agmatine SCHEMBL5665180 | 0.97 | CYP1A2 (0.54) | CYP1A2MEN1KMT2ASMN1; SMN2PAOX | |
| Agmatine SCHEMBL30819275 | 0.97 | — | — | |
| Agmatine SCHEMBL19647 | 0.97 | — | — | |
| Agmatine SCHEMBL8579204 | 0.97 | CYP1A2 (0.54) | CYP1A2MEN1KMT2ASMN1; SMN2PAOX | |
| Agmatine SCHEMBL23364117 | 0.95 | CYP1A2 (0.52) | CYP1A2MEN1KMT2ASMN1; SMN2PAOX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240252664-A1 | PRODUCT AND PROCESS FOR EMPLOYING GC7 (N1-GUANYL-1,7-DIAMINOHEPTANE) BASED ANTIGEN BINDING CONJUGATES IN CANCER THERAPY | DE MAGALHAES NZOLA (US) | 2024-08-01 | — | — | US | claimed |
| US-11865182-B2 | Product and process for employing GC7 (N1-guanyl-1,7-diaminoheptane) based antigen binding conjugates in cancer therapy | DE MAGALHAES NZOLA (US) | 2024-01-09 | — | — | US | claimed |
| US-20200338205-A1 | PRODUCT AND PROCESS FOR EMPLOYING GC7 (N1-GUANYL-1,7-DIAMINOHEPTANE) BASED ANTIGEN BINDING CONJUGATES IN CANCER THERAPY | DE MAGALHAES NZOLA (US) | 2020-10-29 | — | — | US | claimed |
| EP-1049444-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2000-11-08 | — | — | EP | claimed |
| WO-1999037277-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 1999-07-29 | — | — | WO | claimed |
| US-12582625-B2 | Methods for treating neuroblastoma | USWM, LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250186380-A1 | METHODS FOR TREATING FAMILIAL ADENOMATOUS POLYPOSIS | Cancer Prevention Pharmaceuticals (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250127742-A1 | METHODS FOR TREATING NEUROBLASTOMA | OAKTREE FUND ADMINISTRATION, LLC | 2025-04-24 | — | — | US | disclosed |
| US-20240382589-A1 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | THE UNIVERSITY OF TOLEDO (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240307532-A1 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | THE UNIVERSITY OF TOLEDO (US) | 2024-09-19 | — | — | US | disclosed |
| US-20240252664-A1 | PRODUCT AND PROCESS FOR EMPLOYING GC7 (N1-GUANYL-1,7-DIAMINOHEPTANE) BASED ANTIGEN BINDING CONJUGATES IN CANCER THERAPY | DE MAGALHAES NZOLA (US) | 2024-08-01 | — | — | US | disclosed |
| US-20240165063-A1 | METHODS FOR TREATING NEUROBLASTOMA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-23 | — | — | US | disclosed |
| EP-1959010-A2 | Apoptosis-specific eif-5A and polynucleotides encoding same | Senesco Technologies, Inc. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20070154457-A1 | Use of eIF-5A to kill multiple myeloma cells | SENESCO TECHNOLOGIES, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20060287265-A1 | Apoptosis-specific eIF-5A and polynucleotides encoding same | SENESCO TECHNOLOGIES, INC. | 2006-12-21 | — | — | US | disclosed |
| WO-2003106433-A1 | DEOXYHYPUSINE-SYNTHASE INHIBITORS, PHARMACEUTICALS COMPRISING SAID INHIBITORS AND USES THEREOF | VIAXXEL BIOTECH GMBH (DE) | 2003-12-24 | — | — | WO | disclosed |
| US-20030233670-A1 | Gene sequences and uses thereof in plants | MONSANTO TECHNOLOGY LLC | 2003-12-18 | — | — | US | disclosed |
| EP-1291414-A1 | Ex vivo selection of T-cells with reduced alloreactivtiy (diminshed graft-versus-host effect and enhanced graft-verus-leukemia effect) and use therof in bone marrow transplantations | Genethor GmbH (DE) | 2003-03-12 | — | — | EP | disclosed |
| EP-1049444-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037277-A1 | REDUCTION OF HAIR GROWTH | THE GILLETTE COMPANY (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382589-A1 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | EIF2B5, EIF2B1, EIF5B | CYP1A2 4155/4885MEN1 2038/4885KMT2A 1211/4885 |
| US-20240307532-A1 | Synergistic Inhibition of eIF5A and Notch Signaling in Intermediate Tregs | EIF2B5, EIF5B, EIF2B1 | CYP1A2 4224/4885MEN1 1686/4885KMT2A 1958/4885 |
| US-12582625-B2 | Methods for treating neuroblastoma | ODC1, DDC, CD2 | CYP1A2 1850/4885MEN1 380/4885KMT2A 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.